CTLA4 and neoplasm: In particular, tumor-infiltrating immune cells, analysis of gene expression, mismatch-repair deficiency, and/or tumor mutational landscape may play an important role in predicting clinical benefits of CTLA-4 and PD-1/PD-L1 checkpoint inhibitors [12–14].